Current treatment approaches for diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 663-676

  Illidge, Tim ^a,b   Tolan, Shaun ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Diffuse large B cell lymphoma (DLBCL); Radioimmunotherapy; Radiotherapy; Rituximab

Indexed keywords

BLEOMYCIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; VINDESINE;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY CANCER; ELDERLY CARE; FOLLOW UP; GENETIC DISORDER; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION SICKNESS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; TREATMENT OUTCOME;

EID: 42049095763     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701882187     Document Type: Conference Paper

References (46)

1. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M. and Mize, E. M. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
3. Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K. and Hoskins, P. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, pp. 1857-1861.
4. Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, F. and Fisher, R. I. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large - B-cell lymphoma. N Engl J Med, 346, pp. 1937-1947.
5. Henrickson, S. E., Hartmann, E. M., Ott, G. and Rosenwald, A. (2007) Gene expression profiling in malignant lymphomas. Adv Exp Med Biol, 593, pp. 134-146.
6. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J. and Ott, G. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, pp. 275-282.
7. Haarer, C. F., Roberts, R. A., Frutiger, Y. M., Grogan, T. M. and Rimsza, L. M. (2006) Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med, 130, pp. 1819-1824.
8. de Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W. and Lee, A. (2007) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol, 25, pp. 805-812.
9. Coiffier, B. (2003) Increasing chemotherapy intensity in aggressive lymphomas: A renewal?. J Clin Oncol, 21, pp. 2457-2459.
10. Held, G., Schubert, J. and Reiser, M. (2006) Pfreundschuh M, German High-Grade Non-Hodgkin-Lymphoma Study Group. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Semin Hematol, 43, pp. 221-229.
11. Shipp, M. A., Neuberg, D., Janicek, M., Canellos, G. P. and Shulman, J. N. (1995) High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol, 13, pp. 2916-2923.
12. Blayney, D. W., LeBlanc, M. L., Grogan, T., Gaynor, E. R., Chapman, R. A. and Spiridonidis, C. H. (2003) Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol, 21, pp. 2466-2473.
13. Tilly, H., Lepage, E., Coiffier, B., Blanc, M. R. and Bosly, A. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, pp. 4284-4289.
14. Pfreundschuh, M., Trümper, L., Kloess, M., Schmits, R., Feller, A. C. and Rübe, C. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood, 104, pp. 634-641.
15. Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B. and Brice, P. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol, 18, pp. 3025-3030.
16. van Imhoff, G. W., van der Holt, B., Mackenzie, M. A., Veer, M B Van't, Wijermans, P. W. and Ossenkoppele, G. J. (2005) Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: Comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol, 23, p. 3793.
17. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H. and Ma, D. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood, 92, pp. 1927-1932.
18. Vose, J. M., Link, B. K., Grossbard, M. L., Czuczman, M., Grill-Lopez, A. and Gilman, P. (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol, 19, pp. 389-397.
19. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
20. Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A. and Cohn, J. B. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol, 24, pp. 3121-3127.
21. Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M. and Imrie, K. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 7, pp. 379-391.
22. Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K. and Klasa, R. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 23, pp. 5027-5033.
23. Feugier, P., Van Hoof, A., Sebban, C., Sola-Celigny, P., Bouabdallah, R. and Fermé, C. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23, pp. 4117-4126.
24. Coiffier, B., Feugier, P., Mounier, N., Franchi-Rezgui, P., Neste, E Van Den and Macro, M. (2007) Journal of Clinical Oncology, p. 8009.
25. Pfreundschuh, M., Trümper, L., Kloess, M., Schmits, R., Feller, A. C. and Rübe, C. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood, 104, pp. 626-633.
26. Spicer, S., Smith, P., Maclennan, K., Hoskin, P., Hancock, B. and Linch, D. (2004) Long-term follow-up of patients treated with radiotherapy alone for early stage histologically aggressive non-Hodgkin's Lymphoma. British J Cancer, 90, pp. 1151-1155.
27. Miller, T. P., Dahlberg, M. S., Cassady, J. R., Adelstein, D. J., Spier, C. M. and Grogan, T. M. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localised intermediate- and high-grade non-Hodgkin's Lymphoma. N Engl J Med, 339, pp. 21-26.
28. Miller, T. P., LeBlanc, M. and Spier, C. (2001) CHOP alone compared to CHOP versus radiotherapy for early stage aggressive Non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial (abstract). Blood, 98, p. 724.
29. Horning, S. J., Weller, E., Kim, K. M., Earle, J. D., O'Connell, M. J. and Habermann, T. M. (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol, 22, pp. 3032-3038.
30. Reyes, F., Lepage, E., Ganem, G., Molina, T. J., Brice, P. and Coiffier, B. (2005) ACVBP versus CHOP plus radiotherapy for localised aggressive lymphoma. N Engl J Med, 352, pp. 1197-1205.
31. Bonnet, C., Fillet, G., Mournier, N., Ganem, G., Molina, T. J. and Thiéblemont, C. (2007) CHOP alone compare with CHOP plus radiotherapy for localised aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 25, pp. 787-792.
32. Avilés, A., Delgado, S., Nambo, M. J., Alatriste, S. and Díaz-Maqueo, J. C. Adjuvant radiotherapy to sites of precious bulky disease in patients with stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys, 30, pp. 799-803.
33. Moser, E. C., Kluin-Nelemans, H. C., Carde, P., Meerwaldt, J. H., Tirelli, U. and Aleman, B. M. (2006) Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 66, pp. 1168-1177.
34. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J. and de Groot, T. (2002) Early restaging positron emission tomography with 18 F-fuorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's Lymphoma. Ann Oncol, 13, pp. 1356-1363.
35. Kahn, S. T., Flowers, C., Lechowicz, M. J., Hollenbach, K. and Johnstone, P. A. (2006) Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys, 66, pp. 961-965.
36. Hoskin, P. J., Smith, P., Falk, S., Benstead, K., Illidge, T. and Qian, W. (2005) Radiation dose in non-Hodgkin's lymphoma: Preliminary results of a UK NCRN randomised trial. Ann Oncol, 16, p. 59.
37. Laskar, S., Bahl, G., Muckaden, M. A., Gupta, S., Bakshi, A. and Gujral, S. (2007) Primary diffuse large cell B-cell lymphoma of the tonsil. Is a higher radiation dose required?. Cancer
38. Laskar, S., Muckaden, M. A., Bahl, G., de, S., Nair, R., Gupta, S. and Bakshi, A. (2006) Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients. Leuk Lymphoma, 47, pp. 2132-2139.
39. Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J. and Grill-López, A. J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol, 22, pp. 4711-4716.
40. Coiffier, B. (2005) State-of-the-art therapeutics: Diffuse large B-cell lymphoma. J Clin Oncol, 23, pp. 6387-6393.
41. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M. and Lengfelder, E. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol., 9:2, pp. 105-116.
42. Greb, A., Bohlius, J., Trelle, S., Schiefer, D., De Souza, C. A. and Gisselbrecht, C. (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma-results of a comprehensive meta-analysis. Cancer Treat Rev., 33:4, pp. 338-346.
43. Milpied, N., Deconinck, E., Gaillard, F., Delwail, V., Foussard, C. and Berthou, C. (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med, 350, pp. 1287-1295.
44. Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A. and Darif, M. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood, 103, pp. 4429-4431.
45. Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G. and Zinzani, P. L. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110, pp. 54-58.
46. Wilson, W. H., Gutierrez, M., O'Connor, P., Frankel, S., Jaffe, E. and Chabner, B. A. (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol, 29, pp. 41-47.